Aliases & Classifications for Colitis

MalaCards integrated aliases for Colitis:

Name: Colitis 12 74 29 54 6 43 15 17 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0060180
MeSH 43 D003092
NCIt 49 C26723
SNOMED-CT 67 64226004
ICD10 32 K52.9
UMLS 71 C0009319

Summaries for Colitis

Disease Ontology : 12 An inflammatory bowel disease that involves inflammation located in colon.

MalaCards based summary : Colitis is related to microscopic colitis and chemical colitis. An important gene associated with Colitis is NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Tocopherol and Copper have been mentioned in the context of this disorder. Affiliated tissues include colon, t cells and liver, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and Increased viability with MLN4924 (a NAE inhibitor)

Wikipedia : 74 Colitis is an inflammation of the colon. Colitis may be acute and self-limited or long-term. It broadly... more...

Related Diseases for Colitis

Diseases related to Colitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1750)
# Related Disease Score Top Affiliating Genes
1 microscopic colitis 35.0 TNF IL6 IL2 IFNG HLA-DRB1
2 chemical colitis 34.8 TNF NOD2 IL6 IL1B IL17A IL10
3 crohn's colitis 34.7 TNF NOD2 IL2 IL1B IFNG CXCL8
4 ulcerative colitis 34.4 TNF SMAD4 REL NOD2 MPO IRGM
5 inflammatory bowel disease 1 34.1 TNF NOD2 IRGM IL6 IL23R ATG16L1
6 amebiasis 34.1 TNF IL1B IL17A CXCL8
7 inflammatory bowel disease 25, autosomal recessive 33.8 IL10RB IL10RA IL10
8 crohn's disease 33.7 TNF NOD2 IRGM IL6 IL23R IL2
9 pouchitis 33.4 NOD2 CXCL8
10 gastroenteritis 33.4 TNF IL6 IL1B IL10 IFNG CXCL8
11 pyoderma gangrenosum 33.3 TNF NOD2 CXCL8
12 cholangitis, primary sclerosing 33.3 TNF NOD2 MPO IL6 IL17A IL10
13 irritable bowel syndrome 33.3 TNF IL6 IL1B IL10 CXCL8
14 inflammatory bowel disease 33.1 TNF NOD2 MPO IRGM IL6 IL23R
15 bile duct cancer 32.8 SMAD4 IL6 CTNNB1 AKT1
16 lymphoproliferative syndrome, x-linked, 2 32.8 NOD2 IL10RB IL10RA
17 ileocolitis 32.6 TNF NOD2 ATG16L1
18 ileitis 32.4 TNF NOD2 MPO IL6 IL17A IL10
19 proctitis 32.3 TNF NOD2 MPO
20 diarrhea 32.3 TNF NOD2 MPO IL6 IL2 IL1B
21 pyoderma 32.1 TNF NOD2 IL1B CXCL8
22 sclerosing cholangitis 32.1 TNF NOD2 MPO IL6 IL2 IL10
23 cholangitis 31.9 TNF NOD2 MPO IL6 IL2 IL17A
24 cytomegalovirus infection 31.8 TNF IL6 IL1B CXCL8
25 vasculitis 31.8 TNF MPO IL6 IL17A IL10
26 hypereosinophilic syndrome 31.7 MPO IL2 IL10 IFNG CXCL8
27 dysentery 31.6 TNF IL6 IL1B IL10 CXCL8
28 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.5 IL17A IL10 IFNG
29 allergic hypersensitivity disease 31.5 TNF IL2 IL17A IL10 IFNG CXCL8
30 intestinal obstruction 31.5 TNF NOD2 IL6
31 spondyloarthropathy 1 31.5 TNF NOD2 IL23R IL17A
32 pancreatitis 31.5 TNF SMAD4 IL6 IL1B IL10
33 autoimmune disease 31.5 TNF IL6 IL23R IL2 IL1B IL17A
34 severe combined immunodeficiency 31.4 IL6 IL2 IL17A IL10 IFNG
35 pustulosis of palm and sole 31.4 TNF IL17A CXCL8
36 intestinal disease 31.4 TNF NOD2 IL6 IL1B IL17A IL10
37 purpura 31.4 TNF IL6 IL10 IFNG
38 gastritis 31.4 TNF IL6 IL1B IL17A IL10 CXCL8
39 acute pancreatitis 31.4 TNF MPO IL6 IL1B IL10 CXCL8
40 proteasome-associated autoinflammatory syndrome 1 31.4 TNF MPO IL6 IL1B IL17A IL10
41 bronchiectasis 31.3 TNF MPO IL1B CXCL8
42 peritonitis 31.3 TNF MPO IL6 IL1B IL17A IL10
43 thyroiditis 31.3 TNF IL6 IL2 IL10
44 peptic ulcer disease 31.3 TNF IL1B IL10 CXCL8
45 sarcoidosis 1 31.3 TNF NOD2 IL2 IL1B IFNG HLA-DRB1
46 acquired immunodeficiency syndrome 31.3 TNF IL6 IL2 IL1B IL10 IFNG
47 liver disease 31.3 TNF IL6 IL1B CXCL8 AKT1
48 ileus 31.3 TNF IL6 IL1B IL17A IL10 IFNG
49 alopecia 31.3 TNF IL2 IL1B IFNG CTNNB1
50 herpes zoster 31.3 TNF IL2 IL10 IFNG HLA-DRB1

Graphical network of the top 20 diseases related to Colitis:



Diseases related to Colitis

Symptoms & Phenotypes for Colitis

GenomeRNAi Phenotypes related to Colitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-1 9.61 IL2 NOD2
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 9.61 AKT1 IL10 IL1B IL2 MPO NOD2
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.53 AKT1 CXCL8 IL10 IL17A IL1B MPO
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.53 AKT1 CXCL8 IL10 IL17A IL1B IL2

MGI Mouse Phenotypes related to Colitis:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.42 AKT1 ATG16L1 CTNNB1 IFNG IL10 IL10RA
2 homeostasis/metabolism MP:0005376 10.41 AKT1 ATG16L1 CTNNB1 IFNG IL10 IL10RA
3 growth/size/body region MP:0005378 10.39 AKT1 ATG16L1 CTNNB1 IFNG IL10 IL10RB
4 immune system MP:0005387 10.39 AKT1 ATG16L1 CTNNB1 IFNG IL10 IL10RA
5 digestive/alimentary MP:0005381 10.38 ATG16L1 CTNNB1 IFNG IL10 IL10RA IL10RB
6 cellular MP:0005384 10.36 AKT1 ATG16L1 CTNNB1 IFNG IL10 IL10RA
7 cardiovascular system MP:0005385 10.34 AKT1 ATG16L1 CTNNB1 IFNG IL10 IL1B
8 endocrine/exocrine gland MP:0005379 10.3 AKT1 ATG16L1 CTNNB1 IFNG IL10 IL10RB
9 mortality/aging MP:0010768 10.24 AKT1 ATG16L1 CTNNB1 IFNG IL10 IL10RB
10 integument MP:0010771 10.17 AKT1 CTNNB1 IFNG IL10 IL17A IL1B
11 liver/biliary system MP:0005370 10.1 AKT1 CTNNB1 IFNG IL10 IL10RB IL2
12 muscle MP:0005369 9.97 AKT1 ATG16L1 CTNNB1 IFNG IL10 IL6
13 neoplasm MP:0002006 9.96 AKT1 CTNNB1 IFNG IL10 IL1B IL2
14 no phenotypic analysis MP:0003012 9.7 CTNNB1 IFNG IL10 IL17A IL2 IL23R
15 respiratory system MP:0005388 9.65 AKT1 CTNNB1 IFNG IL10 IL10RB IL17A
16 skeleton MP:0005390 9.36 AKT1 CTNNB1 IFNG IL10 IL17A IL1B

Drugs & Therapeutics for Colitis

Drugs for Colitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 463)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
2
Copper Approved, Investigational Phase 4 7440-50-8 27099
3
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
4
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
5
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
6
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
7
Cefpirome Approved Phase 4 84957-29-9 5479539
8
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
9
Linaclotide Approved Phase 4 851199-59-2 65351
10
Teicoplanin Approved, Investigational Phase 4 61036-62-2
11
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
12
Sodium citrate Approved, Investigational Phase 4 68-04-2
13
Nicotine Approved Phase 4 54-11-5 942 89594
14
carbamide peroxide Approved Phase 4 124-43-6
15
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
16
Magnesium citrate Approved Phase 4 3344-18-1
17
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
18
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
19
Ofloxacin Approved Phase 4 82419-36-1 4583
20
Colestipol Approved Phase 4 26658-42-4
21
Ustekinumab Approved, Investigational Phase 4 815610-63-0
22
Tofacitinib Approved, Investigational Phase 4 477600-75-2
23
Certolizumab pegol Approved Phase 4 428863-50-7
24
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
25
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
26
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
27
Caffeine Approved Phase 4 58-08-2 2519
28
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
29
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
30
Losartan Approved Phase 4 114798-26-4 3961
31
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
32
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
33
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
34
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
35
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
36 Tocotrienol Investigational Phase 4 6829-55-6
37 Tocotrienols Phase 4
38 Tocopherols Phase 4
39 Hydrocortisone-17-butyrate Phase 4
40 Polyethylene glycol 3350 Phase 4
41 Copper Supplement Phase 4
42 Nutrients Phase 4
43 Micronutrients Phase 4
44 Trace Elements Phase 4
45 Vitamins Phase 4
46 Ganciclovir triphosphate Phase 4
47 Cyclosporins Phase 4
48 Hematinics Phase 4
49 Iron Supplement Phase 4
50 Heptavalent Pneumococcal Conjugate Vaccine Phase 4

Interventional clinical trials:

(show top 50) (show all 1595)
# Name Status NCT ID Phase Drugs
1 PREDICT UC: Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis - A Randomised Controlled Trial Unknown status NCT02770040 Phase 4 Infliximab
2 Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis: An Open-label,Randomized,Phase IV Clinical Trial Unknown status NCT02962245 Phase 4 berberine;regular treatment
3 Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission. Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
4 Pilot Study to Evaluate the Efficacy of Golimumab for Induction and Maintenance of Clinical and Endoscopic Remission in Patients With Steroid-dependent Ulcerative Colitis Unknown status NCT02412085 Phase 4 Golimumab
5 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Unknown status NCT02998112 Phase 4 fecal microbiota transplantation;Saline
6 Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis. Unknown status NCT01941589 Phase 4 oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone;corticosteroids only
7 Comparison Between Two Therapeutic Strategies for the Maintenance of Clinical and Endoscopic Remission in Patients With Ulcerative Colitis Treated by Infliximab Unknown status NCT03151525 Phase 4 Azathioprine;Infliximab
8 A Randomized, Double-blind Study Investigating the Efficacy and Safety of Mesalazine With Hydrocortisone Sodium Succinate (100mg QD) Enema for 4-Week Treatment in Patients With Ulcerative Colitis (UC) Unknown status NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
9 Probiotic for the Restoration of Intestinal Permeability and Reduction of Intestinal Inflammation in Active Ulcerative Colitis: A Double Blind Randomized Placebo Controlled Trial Unknown status NCT01479660 Phase 4 Probiotic
10 Personalised Medicine: a Break Through Approach for Early Determination of Anti Tumor Necrosis Factor (TNF) Responders and Non Responders Among Patients With Ulcerative Colitis in a Prospective Study With Golimumab (Simponi) Unknown status NCT02186886 Phase 4 Golimumab
11 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation Unknown status NCT01765998 Phase 4 Probiotic;Placebo
12 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
13 The Effect of Probiotics on Bowel Disease Unknown status NCT01078935 Phase 4
14 Efficacy of Proklama on Patients' Symptoms With Irritable Bowel Syndrome: Clinical Trial, Double- Blind, Crossover, Controlled Study vs. Placebo Unknown status NCT02573844 Phase 4 Proklama
15 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
16 A Prospective Multi-centric Belgian Trial to Validate the Use of Golimumab Serum Level Analysis Using the Dried Blood Spot (DBS) Methodology Unknown status NCT02910375 Phase 4
17 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
18 COLITIS: Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe Unknown status NCT01630096 Phase 4 Nu-Lytely
19 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
20 Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205) Completed NCT00219414 Phase 4
21 Preference for a Prefilled Syringe or Smartject™ Device for Delivering SIMPONI (Golimumab) in Patients Suffering From Moderate to Severe Ulcerative Colitis Completed NCT02155335 Phase 4 Prefilled Syringe delivery of Golimumab;Smartject Device delivery of Golimumab
22 Multicentre Investigation of the Efficacy and Safety of Adacolumn® GMA in Patients With Steroid-Dependent Active Ulcerative Colitis and Insufficient Response or Intolerance to Immunosuppressants and/or Biological Therapies Completed NCT01481142 Phase 4
23 A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
24 A Phase IV, Multi-center, Open-label Study to Assess Clinical Recurrence Related to Compliance With Treatment With MMX Mesalamine 2.4g/Day Given Once Daily for the Maintenance of Quiescent Ulcerative Colitis (UC) Completed NCT00446849 Phase 4 MMX Mesalamine
25 Golimumab: A Phase 4, UK, Open Label, Single Arm Study on Its Utilization and Impact in Ulcerative Colitis Completed NCT02092285 Phase 4 Golimumab
26 A Randomized, Multicenter Open Label Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
27 Active Ulcerative Colitis; Placebo Controlled Treatment Trial With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
28 An Open Label, Single Group Assignment Design Study to Correlate Soluble ST2 With Clinical, Endoscopic and Histological Activity in Moderate to Severe Ulcerative Colitis Patients Under Golimumab. Completed NCT02318667 Phase 4
29 An Open-Label, Multicenter and Open Enrollment Model, Postmarketing, Milk-Only Lactation Study to Assess Concentration of Vedolizumab in Breast Milk of Lactating Women With Active Ulcerative Colitis or Crohn's Disease Who Are Receiving Vedolizumab Therapeutically Completed NCT02559713 Phase 4 Vedolizumab
30 Histological and Endoscopic Evaluation of Remission Induced by Infliximab in Moderately to Severely Active Ulcerative Colitis Patients Completed NCT01408810 Phase 4 Infliximab
31 Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease Completed NCT01341808 Phase 4
32 Test Treat Strategy to Prevent Ulcerative Colitis Relapse Completed NCT00652145 Phase 4 mesalamine
33 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication and Adherence in Emergency Ward Completed NCT02246361 Phase 4
34 A Phase 4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/Day MMX Mesalamine/Mesalazine Once Daily in Adult Subjects With Ulcerative Colitis Completed NCT01124149 Phase 4 MMX mesalamine/ mesalazine
35 Multi Center Ulcerative Colitis Pediatric Pentasa Intervention Trial (MUPPIT). A Randomized, Single-blinded, Controlled, Parallel, Induction Therapy With Once vs. Twice Daily Dosing of Pentasa in Pediatric UC. Completed NCT01201122 Phase 4 Mesalamine
36 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) Completed NCT01804166 Phase 4 Infliximab;Golimumab
37 Colon Cleasing for Colonoscopy in Patients With IBD Colitis: Efficacy and Acceptability of 4 Liter PEG vs 2 Liter PEG Plus Bisacodil Completed NCT02248337 Phase 4 Colon preparation for colonoscopy
38 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
39 Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Completed NCT03124121 Phase 4 Golimumab
40 Open Label Safety and Efficacy Trial of Twice Daily Dosing of Asacol vs. Three Times Per Day Dosing for the Induction of Remission in Active Ulcerative Colitis Completed NCT00194818 Phase 4 Asacol (mesalamine)
41 Multicenter Open-label Study Evaluating the Safety and Efficacy of Standardized Initial Therapy Using Either Mesalamine or Corticosteroids Then Mesalamine to Treat Children and Adolescents With Newly Diagnosed Ulcerative Colitis. Completed NCT01536535 Phase 4 Mesalazine;IV Corticosteroid;Oral Corticosteroids
42 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
43 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
44 Serological Response to Pneumococcal Vaccination in Crohn's Disease: A Prospective Multicenter Study Completed NCT01505855 Phase 4 23-valent polysaccharide pneumococcal vaccine
45 Randomized Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients Completed NCT02461758 Phase 4
46 Lactobacillus Casei e Bifidobacterium Breve as Probiotics at the Treatment of Antibiotic Associated Diarrhea: a Randomized Double Blind Study Completed NCT00700557 Phase 4
47 A Randomised Placebo Controlled Trial of "Follow on" Rifaximin for the Prevention of Relapse of Clostridium Associated Diarrhoea Completed NCT01670149 Phase 4 Rifaximin;Placebo
48 Treatment of Iron Deficiency Anaemia in Adults and Adolescents With Inflammatory Bowel Disease Using Ferrous Sulphate: Tolerance and Effects on Haemoglobin, Mood, Quality of Life and Fatigue Completed NCT01991314 Phase 4 Ferrous sulphate
49 Precision Dosing Versus Conventional Dosing of Infliximab Maintenance Therapy: a Randomized Controlled Multicenter Study in Patients With IBD in Clinical Remission Completed NCT02453776 Phase 4 PRECISION dosing Infliximab
50 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4

Search NIH Clinical Center for Colitis

Cochrane evidence based reviews: colitis

Genetic Tests for Colitis

Genetic tests related to Colitis:

# Genetic test Affiliating Genes
1 Colitis 29

Anatomical Context for Colitis

The Foundational Model of Anatomy Ontology organs/tissues related to Colitis:

19
Colon

MalaCards organs/tissues related to Colitis:

40
Colon, T Cells, Liver, Neutrophil, Testes, Bone, Monocytes

Publications for Colitis

Articles related to Colitis:

(show top 50) (show all 30311)
# Title Authors PMID Year
1
Probiotic yeasts: anti-inflammatory potential of various non-pathogenic strains in experimental colitis in mice. 54 61
20440854 2010
2
Colitis as a manifestation of infliximab-associated disseminated cryptococcosis. 54 61
19660974 2010
3
On the benefit of Teucrium in murine colitis through improvement of toxic inflammatory mediators. 61 54
20144954 2010
4
Tumor necrosis factor and interferon-gamma down-regulate Klotho in mice with colitis. 61 54
20004202 2010
5
Cutting edge: IFN-gamma is a negative regulator of IL-23 in murine macrophages and experimental colitis. 61 54
20228197 2010
6
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. 61 54
20181893 2010
7
TLR5 is not required for flagellin-mediated exacerbation of DSS colitis. 54 61
19774646 2010
8
Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice. 61 54
20008145 2010
9
A feed-forward loop involving hyaluronic acid and toll-like receptor-4 as a treatment for colitis? 61 54
19879211 2009
10
The gut feeling of Treg cells: IL-10 is the silver lining during colitis. 54 61
19841645 2009
11
Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. 61 54
19104936 2009
12
All-trans retinoic acid down-regulates inflammatory responses by shifting the Treg/Th17 profile in human ulcerative and murine colitis. 54 61
19477911 2009
13
Methotrexate is effective in reactivated colitis and reduces inflammatory alterations in mesenteric adipose tissue during intestinal inflammation. 61 54
19450685 2009
14
Piroxicam accelerates development of colitis in T-cell receptor alpha chain-deficient mice. 61 54
19446544 2009
15
Supplemental calcium attenuates the colitis-related increase in diarrhea, intestinal permeability, and extracellular matrix breakdown in HLA-B27 transgenic rats. 61 54
19535420 2009
16
Citrobacter rodentium colitis evokes post-infectious hyperexcitability of mouse nociceptive colonic dorsal root ganglion neurons. 54 61
19470777 2009
17
Blocking CD27-CD70 costimulatory pathway suppresses experimental colitis. 61 54
19525396 2009
18
Sleep deprivation worsens inflammation and delays recovery in a mouse model of colitis. 54 61
19403332 2009
19
A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. 61 54
19359427 2009
20
Mitogen-activated protein kinase pathways contribute to hypercontractility and increased Ca2+ sensitization in murine experimental colitis. 54 61
19190174 2009
21
Modulation of inflammatory response via alpha2-adrenoceptor blockade in acute murine colitis. 54 61
19250273 2009
22
Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases. 61 54
19285099 2009
23
Contribution of adenosine A2B receptors to inflammatory parameters of experimental colitis. 61 54
19342675 2009
24
Nitric oxide increases Wnt-induced secreted protein-1 (WISP-1/CCN4) expression and function in colitis. 61 54
19238344 2009
25
Tumor necrosis factor-alpha impairs intestinal phosphate absorption in colitis. 54 61
19196948 2009
26
The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis. 61 54
18612822 2009
27
Dietary taurine attenuates dextran sulfate sodium (DSS)-induced experimental colitis in mice. 61 54
19239157 2009
28
A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. 61 54
18815359 2009
29
Protection from DNBS-induced colitis by the tachykinin NK(1) receptor antagonist SR140333 in rats. 61 54
19103194 2009
30
Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice. 61 54
18618633 2008
31
Treatment with bindarit, an inhibitor of MCP-1 synthesis, protects mice against trinitrobenzene sulfonic acid-induced colitis. 61 54
18827968 2008
32
Blockade of adenosine A2B receptors ameliorates murine colitis. 61 54
18536750 2008
33
Treatment of severe steroid refractory ulcerative colitis. 61 54
18810767 2008
34
Substance P-mediated expression of the pro-angiogenic factor CCN1 modulates the course of colitis. 61 54
18599605 2008
35
The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. 54 61
18535667 2008
36
Tumour necrosis factor alpha in segmental colitis associated with diverticula. 54 61
18049899 2008
37
Suppressor of cytokine signaling-1 ameliorates dextran sulfate sodium-induced colitis in mice. 54 61
18381351 2008
38
Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment. 54 61
18473420 2008
39
Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. 61 54
18400195 2008
40
Human leucocyte antigen and TNFalpha polymorphism association in microscopic colitis. 54 61
18334870 2008
41
Role of M-CSF-dependent macrophages in colitis is driven by the nature of the inflammatory stimulus. 61 54
18202111 2008
42
Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. 61 54
18318598 2008
43
IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. 61 54
18172556 2008
44
Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. 61 54
18219394 2008
45
Hyperbaric oxygen therapy is as effective as dexamethasone in the treatment of TNBS-E-induced experimental colitis. 54 61
17934837 2008
46
Systemic, but not intestinal, IL-7 is essential for the persistence of chronic colitis. 61 54
18097039 2008
47
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. 54 61
18054559 2007
48
IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. 54 61
17918200 2007
49
Curcumin prevents the development of dextran sulfate Sodium (DSS)-induced experimental colitis. 61 54
17429738 2007
50
5-aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model. 54 61
17975166 2007

Variations for Colitis

ClinVar genetic disease variations for Colitis:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CHEK2 NM_007194.4(CHEK2):c.1100del (p.Thr367fs)deletion Conflicting interpretations of pathogenicity 128042 rs555607708 22:29091857-29091857 22:28695869-28695869
2 FLNA NM_001110556.2(FLNA):c.7463C>A (p.Thr2488Asn)SNV Uncertain significance 465020 rs909387820 X:153578106-153578106 X:154349738-154349738
3 CIITA NM_000246.3(CIITA):c.3344G>A (p.Ser1115Asn)SNV Uncertain significance 598994 rs138790505 16:11017111-11017111 16:10923254-10923254

Expression for Colitis

Search GEO for disease gene expression data for Colitis.

Pathways for Colitis

Pathways related to Colitis according to GeneCards Suite gene sharing:

(show top 50) (show all 102)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 TNF REL NOD2 MPO IL6 IL23R
2
Show member pathways
13.97 TNF SMAD4 IL6 IL23R IL2 IL1B
3
Show member pathways
13.83 TNF SMAD4 IL6 IL23R IL2 IL1B
4
Show member pathways
13.69 TNF SMAD4 IL6 IL2 IL1B IL17A
5
Show member pathways
13.57 TNF IL6 IL23R IL2 IL1B IL17A
6
Show member pathways
13.39 TNF NOD2 IL6 IL23R IL2 IL1B
7
Show member pathways
13.37 TNF SMAD4 IL6 IL23R IL2 IL1B
8
Show member pathways
13.22 TNF SMAD4 IL6 IL2 IL1B IL10
9
Show member pathways
13.11 TNF IL6 IL1B IL10RB IL10RA CXCL8
10 13.03 SMAD4 IL6 IL23R IL2 IFNG CXCL8
11
Show member pathways
13.02 TNF IL6 IL2 IL1B IL17A IL10
12
Show member pathways
13 TNF IL6 IL2 IL1B IFNG HLA-DRB1
13 12.92 TNF IL6 IL1B IFNG HLA-DRB1 AKT1
14
Show member pathways
12.86 TNF REL NOD2 IL6 IL1B CXCL8
15
Show member pathways
12.84 TNF REL IL6 IL2 IL1B AKT1
16
Show member pathways
12.81 TNF REL IL2 IL10RB IL10RA IL10
17
Show member pathways
12.76 TNF REL IL1B IFNG AKT1
18
Show member pathways
12.76 TNF REL IL6 IL2 IL1B IL17A
19 12.74 TNF REL MPO IL2 IL1B IL17A
20
Show member pathways
12.65 IL6 IL23R IL2 IL10RB IL10RA IL10
21
Show member pathways
12.54 TNF IL6 IL2 IL10RB IL10RA IL10
22 12.53 TNF IL1B CXCL8 ATG16L1 AKT1
23 12.53 TNF SMAD4 IL6 IL2 HLA-DRB1 AKT1
24
Show member pathways
12.52 TNF MPO IL6 IL2 IL1B IFNG
25
Show member pathways
12.51 TNF REL IL6 IL1B IL17A IFNG
26
Show member pathways
12.5 TNF IL6 IL1B IFNG CXCL8 AKT1
27 12.5 TNF IL6 IL1B CXCL8 CTNNB1 AKT1
28 12.44 TNF NOD2 IL6 IL1B CXCL8 ATG16L1
29
Show member pathways
12.41 TNF IL6 IL2 IL1B IL17A IL10
30
Show member pathways
12.4 REL IL6 CTNNB1 AKT1
31
Show member pathways
12.39 REL NOD2 IL1B AKT1
32 12.39 TNF SMAD4 IL6 IFNG CTNNB1 AKT1
33
Show member pathways
12.39 TNF REL IL6 IL1B IFNG CXCL8
34
Show member pathways
12.39 TNF REL IL6 IL2 IL1B IL10
35 12.37 TNF IL6 IL1B IL10 CXCL8 CTNNB1
36 12.36 IL23R IL10RB IL10RA ATG16L1
37 12.36 REL MPO IL6 CXCL8
38 12.36 TNF IL6 IL1B CXCL8
39
Show member pathways
12.35 TNF REL IL6 CXCL8
40
Show member pathways
12.3 TNF IRGM IL1B IL10RB IL10RA IL10
41 12.27 TNF IL1B IFNG CTNNB1 AKT1
42
Show member pathways
12.27 TNF SMAD4 NOD2 IL6 IL23R IL2
43 12.23 TNF IL6 IL2 IL1B IFNG CXCL8
44 12.21 TNF MPO IL6 IL2 IL10 IFNG
45 12.21 TNF IL6 IL2 IL1B IL10 CXCL8
46
Show member pathways
12.2 SMAD4 IL6 IL10 AKT1
47 12.17 TNF IL1B IFNG AKT1
48
Show member pathways
12.17 REL IL2 IL1B IFNG HLA-DRB1
49 12.16 TNF NOD2 IL6 IL1B AKT1
50 12.16 SMAD4 IL6 IL1B IFNG CXCL8 ATG16L1

GO Terms for Colitis

Cellular components related to Colitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 TNF MPO IL6 IL2 IL1B IL17A

Biological processes related to Colitis according to GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.17 MPO IL6 IL2 IL10 CTNNB1 AKT1
2 positive regulation of gene expression GO:0010628 10.16 TNF IL6 IL1B IFNG CTNNB1 AKT1
3 positive regulation of cell proliferation GO:0008284 10.16 NOD2 IL6 IL2 IL1B IFNG CTNNB1
4 negative regulation of cell proliferation GO:0008285 10.15 SMAD4 IL6 IL1B IL10 CXCL8 CTNNB1
5 positive regulation of transcription by RNA polymerase II GO:0045944 10.14 TNF SMAD4 REL NOD2 IL6 IL2
6 positive regulation of transcription, DNA-templated GO:0045893 10.11 TNF SMAD4 REL IL6 IL1B IL10
7 negative regulation of gene expression GO:0010629 10.1 TNF REL IFNG CTNNB1 AKT1
8 defense response to bacterium GO:0042742 10.08 TNF NOD2 MPO IRGM IL10
9 response to lipopolysaccharide GO:0032496 10.04 MPO IL23R IL1B IL10RA IL10
10 defense response GO:0006952 10.02 TNF NOD2 MPO IRGM CXCL8
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.01 TNF NOD2 IL6 IL1B
12 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.01 TNF REL NOD2 IL1B HLA-DRB1 CTNNB1
13 positive regulation of inflammatory response GO:0050729 9.97 TNF IL2 IL1B IFNG
14 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.96 TNF IRGM IL6 AKT1
15 cellular response to organic cyclic compound GO:0071407 9.94 TNF NOD2 IL1B AKT1
16 positive regulation of T cell proliferation GO:0042102 9.93 IL6 IL23R IL2 IL1B
17 regulation of insulin secretion GO:0050796 9.92 TNF IL1B IFNG
18 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.92 TNF REL AKT1
19 response to glucocorticoid GO:0051384 9.92 TNF IL6 IL10
20 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.91 TNF NOD2 IL1B
21 negative regulation of neuron death GO:1901215 9.91 REL CTNNB1 AKT1
22 positive regulation of smooth muscle cell proliferation GO:0048661 9.91 TNF IL6 AKT1
23 positive regulation of autophagy GO:0010508 9.91 IRGM IFNG ATG16L1
24 positive regulation of DNA-binding transcription factor activity GO:0051091 9.91 TNF IL6 IL1B IL10 CTNNB1 AKT1
25 positive regulation of protein phosphorylation GO:0001934 9.91 TNF IRGM IL2 IL1B IFNG HLA-DRB1
26 humoral immune response GO:0006959 9.9 TNF IL6 IFNG
27 positive regulation of protein localization to plasma membrane GO:1903078 9.9 TNF IFNG AKT1
28 negative regulation of autophagy GO:0010507 9.9 IL10RA IL10 AKT1
29 positive regulation of interleukin-6 production GO:0032755 9.9 TNF NOD2 IL6 IL1B
30 positive regulation of phagocytosis GO:0050766 9.89 TNF IL1B IFNG
31 positive regulation of interferon-gamma production GO:0032729 9.89 TNF IL23R IL2 IL1B
32 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 TNF IL6 IL23R IL2 IFNG
33 protein kinase B signaling GO:0043491 9.88 TNF IL1B AKT1
34 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.88 TNF IL1B AKT1
35 positive regulation of epithelial to mesenchymal transition GO:0010718 9.88 SMAD4 IL6 IL1B CTNNB1
36 lipopolysaccharide-mediated signaling pathway GO:0031663 9.87 TNF IL1B AKT1
37 positive regulation of cytokine secretion GO:0050715 9.87 TNF IL10 IFNG
38 positive regulation of nitric oxide biosynthetic process GO:0045429 9.87 TNF IL1B IFNG AKT1
39 cellular response to lipopolysaccharide GO:0071222 9.87 TNF NOD2 IRGM IL6 IL1B IL10
40 regulation of synapse organization GO:0050807 9.86 TNF IL10RA IL10
41 positive regulation of interleukin-8 production GO:0032757 9.86 TNF NOD2 IL1B
42 positive regulation of interleukin-6 secretion GO:2000778 9.86 TNF IL1B IL17A IFNG
43 negative regulation of neurogenesis GO:0050768 9.85 TNF IL6 IL1B CTNNB1
44 immune response GO:0006955 9.85 TNF IL6 IL2 IL1B IL17A IL10RB
45 positive regulation of glial cell proliferation GO:0060252 9.83 TNF IL6 IL1B
46 astrocyte activation GO:0048143 9.83 TNF IL1B IFNG
47 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.83 TNF IL1B IFNG
48 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.83 TNF NOD2 IL6 IL17A
49 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.82 TNF IL1B IL10
50 positive regulation of interleukin-17 production GO:0032740 9.81 NOD2 IL23R IL2

Molecular functions related to Colitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.96 TNF SMAD4 REL NOD2 MPO IRGM
2 cytokine receptor activity GO:0004896 9.43 IL23R IL10RB IL10RA
3 cytokine activity GO:0005125 9.23 TNF IL6 IL2 IL1B IL17A IL10
4 interleukin-10 receptor activity GO:0004920 9.16 IL10RB IL10RA

Sources for Colitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....